S&P 500   5,031.78 (-0.39%)
DOW   37,692.04 (-0.28%)
QQQ   427.88 (-0.75%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.78 (-0.39%)
DOW   37,692.04 (-0.28%)
QQQ   427.88 (-0.75%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.78 (-0.39%)
DOW   37,692.04 (-0.28%)
QQQ   427.88 (-0.75%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.78 (-0.39%)
DOW   37,692.04 (-0.28%)
QQQ   427.88 (-0.75%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
NASDAQ:DYN

Dyne Therapeutics (DYN) Stock Price, News & Analysis

$24.48
-0.15 (-0.61%)
(As of 11:37 AM ET)
Today's Range
$24.38
$25.09
50-Day Range
$21.44
$29.18
52-Week Range
$6.40
$30.27
Volume
167,923 shs
Average Volume
2.04 million shs
Market Capitalization
$2.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.43

Dyne Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
52.0% Upside
$37.43 Price Target
Short Interest
Bearish
16.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of Dyne Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$44.69 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.25) to ($3.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.38 out of 5 stars

Medical Sector

281st out of 930 stocks

Pharmaceutical Preparations Industry

123rd out of 433 stocks

DYN stock logo

About Dyne Therapeutics Stock (NASDAQ:DYN)

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Stock Price History

DYN Stock News Headlines

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Dyne Therapeutics Appoints John Cox As CEO To Succeed Joshua Brumm
Dyne Therapeutics Announces CEO Transition
Dyne Therapeutics (NASDAQ: DYN)
DYN Apr 2024 30.000 put
DYN Apr 2024 22.500 call
DYN Apr 2024 30.000 call
Dyne: H2 2024 Muscle Disease Data Could Boost Value
See More Headlines
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
4/17/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DYN
Employees
141
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.43
High Stock Price Target
$56.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+52.0%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-235,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.49 per share

Miscellaneous

Free Float
68,279,000
Market Cap
$2.12 billion
Optionable
Optionable
Beta
0.95
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

DYN Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DYN shares.
View DYN analyst ratings
or view top-rated stocks.

What is Dyne Therapeutics' stock price target for 2024?

7 equities research analysts have issued twelve-month price targets for Dyne Therapeutics' shares. Their DYN share price targets range from $22.00 to $56.00. On average, they predict the company's share price to reach $37.43 in the next year. This suggests a possible upside of 52.0% from the stock's current price.
View analysts price targets for DYN
or view top-rated stocks among Wall Street analysts.

How have DYN shares performed in 2024?

Dyne Therapeutics' stock was trading at $13.30 at the beginning of 2024. Since then, DYN stock has increased by 85.2% and is now trading at $24.63.
View the best growth stocks for 2024 here
.

Are investors shorting Dyne Therapeutics?

Dyne Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,080,000 shares, an increase of 18.5% from the March 15th total of 6,820,000 shares. Based on an average daily volume of 1,710,000 shares, the short-interest ratio is presently 4.7 days. Currently, 16.2% of the company's stock are short sold.
View Dyne Therapeutics' Short Interest
.

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our DYN earnings forecast
.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by $0.17.

What ETFs hold Dyne Therapeutics' stock?
When did Dyne Therapeutics IPO?

Dyne Therapeutics (DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vida Ventures Advisors LLC (0.47%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell.
View institutional ownership trends
.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DYN) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners